It can be noted that SEMA3F, now recognised as a tumour suppressor gene (Xiang et al, 2002; Kessler et al, 2004; Bielenberg et al, 2004; Kusy et al, 2005; Futamura et al, 2007) with antiangiogenic (Kessler et al, 2004; Futamura et al, 2007) and anti-metastatic properties (Bielenberg et al, 2004), did not show up as an important gene in our cohort of patients with gliomas. This evidence concerns the gene SEMA3F and glioma.